Homozygous Familial Hypercholesterolemia (HoFH) Treatments

Find Homozygous Familial Hypercholesterolemia (HoFH) Treatments

Generic Name

Atorvastatin

Brand Names

Dicyclomine, Amlodipine Besylate, Amlodipine, Sdamlo, Olmesartan Medoxomil, Benazepril, Caduet, Azor, Tribenzor, Atorvaliq, Katerzia, Benicar, Lotrel, Olmesartan Medoxomil Amlodipine, Lipitor, Norliqva, Norvasc, Lotensin

FDA approval date: September 30, 1974

Classification: HMG-CoA Reductase Inhibitor

Form: Injection, Tablet, Suspension, Capsule, Solution

What is Dicyclomine (Atorvastatin)?

Atorvastatin calcium tablets are indicated: To reduce the risk of: Myocardial infarction , stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia . As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia . As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia Hypertriglyceridemia Atorvastatin calcium is an HMG-CoA reductase inhibitor indicated : To reduce the risk of: Myocardial infarction , stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease but without clinically evident CHD. MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD. As an adjunct to diet to reduce low-density lipoprotein in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia . As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia. As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Prospective Observational Study on the Effect of Improving Blood Lipid Management on the Clinical Prognosis of Symptomatic Intracranial Atherosclerotic Stenosis（sICASBLM）

Enrollment Status: Recruiting

Publish Date: April 15, 2026

Intervention Type: Drug

Study Phase: Not Applicable

Summary: sICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C\>1.8mmol/L) without endovascular therapy.

A Multi-Center, Randomized, Open-label, Parallel, Controlled Phase Ⅳ Clinical Trial to Evaluate the Effect of Inclisiran on Coronary Atherosclerotic Plaque in Patients With Acute Myocardial Infarction and Elevated Low-density Lipoprotein Cholesterol

Enrollment Status: Recruiting

Publish Date: April 14, 2026

Intervention Type: Drug, Procedure

Study Phase: Phase 4

Summary: This study is to evaluate the effect of Inclisiran on coronary atherosclerosis using intravascular ultrasound (IVUS) and optical coherence tomography (OCT) in patients with acute myocardial infarction and elevated low-density lipoprotein cholesterol (LDL-C).

Load-Dependent Arterial Stiffness to Optimize Blood Pressure Management in Older Veterans (LOADED BP)

Enrollment Status: Recruiting

Publish Date: April 13, 2026

Intervention Type: Other

Study Phase: Not Applicable

Summary: Hypertension is a common and treatable disorder that remains the leading preventable cause of heart disease. Blood pressure treatment relies mainly on upper arm blood pressure readings and ignores blood vessel physiology and underlying individual genetic information. Older Veterans with hypertension are less likely to be treated to goal blood pressure because there are conflicting recommendations ...

View All Clinical Trials